Posted 13 September, 2023
Immune Therapeutics, Inc. appointed Noreen Griffin as new CEO
OTC:IMUN appointed new Chief Executive Officer Noreen Griffin in a 8-K filed on 13 September, 2023.
Appointment of Noreen Griffin as Chief Executive Officer
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Immune Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Biostax Corp. engages in the development and marketing of pharmaceutical, biotechnology, and MedTech products. The company was founded by Noreen Griffin on December 2, 1993 and is headquartered in Winter Park, FL.Market Cap
$3.97M
View Company Details
$3.97M
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Robert Wilson as President On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the "Company"), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately. Mr. Wilson's resignation was not the result of any material dispute or disagreement on any matter relating to the operations, policies, or practices of the Company. Resignation of Kelly Wilson as Chief Executive Officer On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Company, delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately. Ms. Wilson's resignation was not the result of any material dispute or disagreement on any matter relating to the operations, policies or practices of the Company. Appointment of Noreen Griffin as Chief Executive Officer On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer. Ms. Griffin, age 70, served as the Vice President of the Company from November 2022 to July 2023. Since November 2012, Ms. Griffin has also served as Manager of TNI Biotech International Ltd., a subsidiary of the Company. Since January 2021, Ms. Griffin has also been a director and Chief Executive Officer of Forte Animal Health Inc. From March 2012 to September 2019, Ms. Griffin, a co-founder of the Company, was Chief Executive Officer and a director of the Company. From April 2020 to September 2020, Ms. Griffin was Chief Executive Officer and President, respectively, of Cytocom, Inc. prior to its merger with Cleveland BioLabs, Inc., now known as Statera Biopharma, Inc. (OTC Expert Market: STAB), a clinical-stage biopharmaceutical company and former subsidiary of the Company. From September 2020 to April 2022, Ms. Griffin was Vice President of Business Development at Statera Biopharma, Inc. Ms. Griffin attended North Florida Community College from 1978 to 1980 and left prior to graduation in order to pursue full-time employment opportunities. Griffin Consulting Agreement In connection with Ms. Griffin's appointment as Chief Executive Officer, under an executive consultant agreement between Ms. Griffin and the Company, dated August 2, 2023 (the "Griffin Consulting Agreement"), Ms. Griffin agreed to provide a minimum of 40 hours of service to the Company per week as an independent consultant in connection with her duties as Chief Executive Officer. Under the Griffin Consulting Agreement, Ms. Griffin will be paid a monthly fee of $20,834. The Griffin Consulting Agreement provided for the deferral and accrual of Ms. Griffin's salary from the commencement of the term of the Griffin Consulting Agreement until the Company has reached a funding threshold of at least $1,000,000, at which point the entire accrued amount of Ms. Griffin's salary, plus accrued interest at an annual interest rate of 8.50%, accruing on a monthly basis, will become due and payable. Ms. Griffin will be paid a medical insurance stipend of up to $1,200 per month to cover medical insurance premiums for Ms. Griffin and her dependents and health savings account contributions until such time that the Company can make available an alternative medical insurance plan. Ms. Griffin must be reimbursed for reasonable and necessary out-of-pocket business, entertainment, and travel expenses in connection with her duties in accordance with the Company's expense reimbursement policies and procedures, provided that any expense above $5,000 must be first approved by the Company's Chief Financial Officer. The Griffin Consulting Agreement also provided for indemnification of Ms. Griffin as an officer of the Company. The initial term of the Griffin Consulting Agreement will be from August 2, 2023 to August 1, 2024 and will renew automatically for up to three additional one-year terms unless notice is given in writing 30 days prior to the end of each term. The Griffin Consulting Agreement may be terminated without cause by either party with 30 days' written notice. The Griffin Consulting Agreement also contains customary non-disclosure and non-disparagement provisions. The foregoing description of the Griffin Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Griffin Consulting Agreement filed as Exhibit 10.1 to this report, which is incorporated by reference herein. There are no arrangements or understandings between Ms. Griffin and any other persons pursuant to which she was selected as Chief Executive Officer. Ms. Griffin is the mother of Robert Wilson, a director and Vice President of the Company, and the mother-in-law of Kelly Wilson, President of the Company. Ms. Griffin is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K. Appointment of Kelly Wilson as President In connection with the appointment of Noreen Griffin as Chief Executive Officer, Kelly Wilson was appointed President of the Company effective July 25, 2023. Ms. Wilson, age 52, served as Chief Executive Officer of the Company from April 2023 to July 2023, as Chief Operating Officer of the Company since August 2022, and as Interim President and Interim Chief Executive Officer of the Company from November 2022 to April 2023. From 2013 to April 2020, Ms. Wilson was the Company's Chief Technology Officer. From September 2014 to April 2020, Ms. Wilson also served as Chief Technology and Information Officer of Cytocom, Inc. prior to its merger with Cleveland BioLabs, Inc., now known as Statera Biopharma, Inc. (OTC Expert Market: STAB), a clinical-stage biopharmaceutical company and former subsidiary of the Company. From April 2020 to April 2022, Ms. Wilson was also Director of Program and Project Management of Statera Biopharma, Inc. From May 2022 to July 2022, Ms. Wilson was Chief Operating Officer of Biostax, Inc., an immunotherapy startup. Ms. Wilson graduated with honors from the University of Central Florida with a master's degree in systems design and a bachelor's degree in English. As compensation for services to be rendered to the Company by Ms. Wilson in her official capacity as President, Ms. Wilson will continue to receive compensation under her executive consulting agreement, dated November 1, 2022, as amended on April 13, 2023, and as previously disclosed on a Current Report on Form 8-K filed on April 20, 2023. There are no arrangements or understandings between Ms. Wilson and any other persons pursuant to which she was selected as President. Ms. Wilson is married to Robert Wilson, a director and Vice President of the Company, and is the daughter-in-law of Ms. Griffin, Chief Executive Officer of the Company. Ms. Wilson is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.